|Dr. J. Joseph Kim Ph.D.||Chief Exec. Officer, Pres and Director||1.03M||1.51M||48|
|Mr. Peter D. Kies||Chief Financial Officer||538.36k||N/A||54|
|Dr. Niranjan Y. Sardesai Ph.D.||Chief Operating Officer||575.44k||90.74k||49|
|Dr. Mark L. Bagarazzi M.D.||Chief Medical Officer||576.45k||N/A||56|
|Mr. Bernie Hertel||VP of Investor Relations and Communications||N/A||N/A||N/A|
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 3; Compensation: 9.